Placebo News and Research

RSS

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

The results of a randomized, double-blind, placebo-controlled clinical trial showed that Cognizin citicoline (Jarrow Formulas) was effective at reducing cocaine use, based on urine drug screens, in patients with bipolar disorder and cocaine dependence. The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin citicoline or placebo add-on therapy for 12 weeks.

7 Jul 2015

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator.

7 Jul 2015

Bacterial biofilms play role in development of systemic lupus erythematosus

Lupus, multiple sclerosis, and type-1 diabetes are among more than a score of diseases in which the immune system attacks the body it was designed to defend. But just why the immune system begins its misdirected assault has remained a mystery.

7 Jul 2015

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

7 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC).

3 Jul 2015

Gene therapy improves lung function in patients with cystic fibrosis

Gene therapy was shown to provide significant benefits for patients with cystic fibrosis in a recent clinical study published in The Lancet Respiratory Medicine journal.

3 Jul 2015

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

3 Jul 2015

Gene therapy for cystic fibrosis shows significant benefit in lung function

For the first time gene therapy for cystic fibrosis has shown a significant benefit in lung function compared with placebo, in a phase 2 randomised trial published in The Lancet Respiratory Medicine journal. The technique replaces the defective gene response for cystic fibrosis by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells.

3 Jul 2015

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people with moderate vitamin B12 deficiency, according to a new study published in the American Journal of Clinical Nutrition.

3 Jul 2015

Testosterone, cortisol hormones may destabilise financial markets by making traders take more risks

The hormones testosterone and cortisol may destabilise financial markets by making traders take more risks, according to a study. Researchers simulated the trading floor in the lab by having volunteers buy and sell assets among themselves. They measured the volunteers' natural hormone levels in one experiment and artificially raised them in another.

3 Jul 2015

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

A novel synthetic hormone that makes certain skin cells produce more melanin significantly increases pain-free sun exposure in people with erythropoietic protoporphyria, a rare, genetic disorder resulting in excruciating pain within minutes of sun exposure.

3 Jul 2015

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients.

2 Jul 2015

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

2 Jul 2015

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.

2 Jul 2015

Cortisol study may explain persistence of emotional memories occurring in anxiety, PTSD

The stress hormone cortisol strengthens memories of scary experiences. However, it is effective not only while the memory is being formed for the first time, but also later when people look back at an experience while the memory reconsolidates. This has been published by cognition psychologists from the Ruhr-Universität Bochum in the journal "Neuropsychopharmacology".

2 Jul 2015

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

2 Jul 2015

UCSD researchers report that statins make women aggressive, but men calmer

Statins are a hugely popular drug class used to manage blood cholesterol levels and reduce the risk of heart disease. Previous studies had raised questions about adverse behavioral changes with statins, such as irritability or violence, but findings with statins have been inconsistent. In the first randomized trial to look at statin effects on behavior, researchers at the University of California, San Diego School of Medicine report that aggressive behavior typically declined among men placed on statins (compared to placebo), but typically increased among women placed on statins.

2 Jul 2015

ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has been granted a product license by the Health Canada Natural and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome in Canada.

1 Jul 2015

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.

1 Jul 2015

Placebo News and Research

Cognizin citicoline shows promise in patients with bipolar disorder and cocaine dependence

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Bacterial biofilms play role in development of systemic lupus erythematosus

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Gene therapy improves lung function in patients with cystic fibrosis

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Gene therapy for cystic fibrosis shows significant benefit in lung function

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people

Testosterone, cortisol hormones may destabilise financial markets by making traders take more risks

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

Study demonstrates the important role of placebo effect in medical care

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

Cortisol study may explain persistence of emotional memories occurring in anxiety, PTSD

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

UCSD researchers report that statins make women aggressive, but men calmer

ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ALS ACT initiative to speed discovery of new ALS treatments

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News